Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
노바스템
2024-04-18
조회수 257
This review critically assesses the performance of anti-angiogenic therapies targeting VEGF/VEGFR in cancer, highlighting the disparity between the success in animal models and less impressive results in humans. Initiated from Judah Folkman's pioneering idea that angiogenesis is essential for tumor growth, anti-VEGF therapies have shown promise in preclinical models but have yielded only modest benefits in clinical settings. The review discusses several key issues contributing to these limitations, such as the heterogeneity of tumor vasculature, where different vessel types respond variably to anti-VEGF treatments. Most human and mouse tumors are supplied by at least six well-defined blood vessel types that arise by both angiogenesis and arterio-venogenesis, and interestingly, not all these vessel types maintain dependency on VEGF after formation, limiting the effectiveness of anti-VEGF therapies. The review suggests that for more significant impacts on human cancer, future therapies may need to target additional markers or molecules present on these resistant blood vessels.
The detailed understanding of blood vessel types in tumors and their responses to VEGF-targeting therapies can provide valuable insights for Novastem’s approaches in stem cell therapies. Just as cancer therapies must consider the heterogeneity of tumor vasculature, stem cell therapies could benefit from tailored approaches that consider the varied environments and requirements of different tissue types, potentially using stem cells to target specific pathways or conditions within diseased or damaged tissues.
Vessel Heterogeneity and Therapy Resistance: The existence of multiple types of blood vessels within tumors, each with different susceptibilities to VEGF-targeted therapies, underscores the complexity of effectively treating all tumor components.
Beyond VEGF Targeting: The limitations observed with current anti-VEGF therapies highlight the need for multi-target strategies that address other pathways involved in vessel maturation and tumor survival.
Implications for Regenerative Medicine: Insights from the failure and success of these cancer therapies can direct the development of more effective regenerative treatments, potentially influencing how stem cell therapies are designed and implemented to manage or repair tissue at the vascular level.
This review critically assesses the performance of anti-angiogenic therapies targeting VEGF/VEGFR in cancer, highlighting the disparity between the success in animal models and less impressive results in humans. Initiated from Judah Folkman's pioneering idea that angiogenesis is essential for tumor growth, anti-VEGF therapies have shown promise in preclinical models but have yielded only modest benefits in clinical settings. The review discusses several key issues contributing to these limitations, such as the heterogeneity of tumor vasculature, where different vessel types respond variably to anti-VEGF treatments. Most human and mouse tumors are supplied by at least six well-defined blood vessel types that arise by both angiogenesis and arterio-venogenesis, and interestingly, not all these vessel types maintain dependency on VEGF after formation, limiting the effectiveness of anti-VEGF therapies. The review suggests that for more significant impacts on human cancer, future therapies may need to target additional markers or molecules present on these resistant blood vessels.
The detailed understanding of blood vessel types in tumors and their responses to VEGF-targeting therapies can provide valuable insights for Novastem’s approaches in stem cell therapies. Just as cancer therapies must consider the heterogeneity of tumor vasculature, stem cell therapies could benefit from tailored approaches that consider the varied environments and requirements of different tissue types, potentially using stem cells to target specific pathways or conditions within diseased or damaged tissues.
#AntiVEGF #CancerTherapy #TumorAngiogenesis #VascularHeterogeneity #StemCellTherapy #RegenerativeMedicine #Novastem #VEGFR